Olmesartan (brand name Benicar) is an antihypertensive drug clinicians commonly use to treat high blood pressure. Olmesartan induced enteropathy (OSE) is a rare entity that authors first identified in 2012. The etiological basis of OSE remains unclear, although authors have suggested that this condition could be due to alternations in cell mediated immune responses induced by the drug. The objective of the case report is to describe a patient who presented with diarrhea and was eventually diagnosed with OSE. A female patient in her later 60s presented to an emergency room after two recent hospitalizations with profound diarrhea, generalized weakness and weight loss. She underwent a diagnostic workup including endoscopy and colonoscopy. The patient's endoscopy with duodenal biopsy revealed villous atrophy with attenuated and blunted villi with intraepithelial CD3 positive T lymphocytes, suggestive of gluten-induced enteropathy. When the patient's symptoms did not improve after the authors placed her on a gluten free diet for a few days, they further investigated her for secretory diarrhea, including Gastrin, Somatostatin and Vasoactive Intestinal Peptide lab values that they found to be within normal limits. Due to the patient's lack of improvement with initial treatment, the authors suspected OSE and stopped her olmesartan and the patients' symptoms gradually improved in three weeks.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7746095 | PMC |
http://dx.doi.org/10.51894/001c.6383 | DOI Listing |
Pharmaceutics
December 2024
Faculty of Pharmacy, "Victor Babeş" University of Medicine and Pharmacy, 2 Eftimie Murgu Square, 300041 Timisoara, Romania.
Olmesartan medoxomil (OLM) is the prodrug of olmesartan, an angiotensin II type 1 receptor blocker that has antihypertensive and antioxidant activities and renal protective properties. It exhibits low water solubility, which leads to poor bioavailability and limits its clinical potential. To improve the solubility of OLM, a host-guest inclusion complex (IC) between heptakis(2,6-di-O-methyl)-β-cyclodextrin (DMβCD) and the drug substance was obtained.
View Article and Find Full Text PDFCase Rep Med
December 2024
Department of Gastroenterology, Gastrocentro Natal, Natal, Rio Grande do Norte, Brazil.
The case involves a 63-year-old hypertensive man, taking antihypertensive medication (olmesartan) for the previous two years, who sought medical attention due to voluminous diarrhea, with several episodes per day and weight loss of 10 kg. He was submitted to a series of diagnostic procedures without elucidation and empirical treatment with unsuccessful outcome. After hospitalization for clinical stabilization and for presenting with duodenal atrophy, obtained by duodenal biopsy associated with negative markers for celiac disease, the patient was diagnosed with suspected olmesartan-induced enteropathy, showing rapid improvement of diarrhea after the drug was withdrawn, with weight regain in 6 months and normalization of the duodenal histological picture after 10 months.
View Article and Find Full Text PDFCureus
October 2024
Gastroenterology, Sutter Santa Rosa Regional Hospital, Santa Rosa, USA.
Collagenous sprue (CS) is a rare autoimmune gastrointestinal disorder characterized by specific histologic changes in the small intestine. It often presents with more severe symptoms and a worse prognosis compared to celiac disease, including significant malabsorption, weight loss, and nutrient deficiencies. Despite treatment with a gluten-free diet, symptom improvement is limited, with only a small fraction of patients responding positively.
View Article and Find Full Text PDFMed Clin (Barc)
December 2024
Centre for Research on Drug Safety (CESME), Department of Cell Biology, Histology, Pharmacology and Genetics, Faculty of Medicine, University of Valladolid (Centro de Estudios Sobre la Seguridad de los Medicamentos (CESME), Departamento de Biología Celular, Histología, Farmacología y Genética, Facultad de Medicina, Universidad de Valladolid), Valladolid, Spain; Research Group Pharmacogenetics, Cancer Genetics, Genetic Polymorphisms and Pharmacoepidemiology, University of Valladolid (GIR Farmacogenética, Genética del Cáncer, Polimorfismos Genéticos y Farmacoepidemiología, Universidad de Valladolid), Spain. Electronic address:
Lancet
October 2024
Department of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!